Dikkat eksikliği hiperaktivite bozukluğu olan bir ergende modifiye salımlı metilfenidat kaynaklı Raynaud fenomeni

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental commencing before the age of 12 years and characterized by developmentally inappropriate inattention, hyperactivity, and/or impulsivity symptoms. Stimulants such as methylphenidate (MPH) are used first-line therapy for children with ADHD. Psychostimulants may be associated vascular problems. Raynaud’s phenomenon (RP) peripheral vasculopathy potentially connective tissue diseases recurring reversible vasospasm attacks triggered cold emotional stress. Several cases have been published involving RP observed MPH. The present report discusses 14-year-old girl ADHD who experienced addition 10 mg modified-release MPH during 27 osmotic release (OROS)-MPH therapy, but not 36 OROS-MPH therapy.